Julie Torode Discusses the WHO Cervical Cancer Elimination Strategy


The director of special projects at the Union for International Cancer Control spoke about the strategy released by the World Health Organization and what needs to occur to achieve the goals laid out by the organization.

Following a call from the World Health Organization (WHO) Director General in 2018, a global strategy was developed by the organization to accelerate the elimination of cervical cancer as a public health problem.

The strategy established goals and targets from 2020 to 2030 with a focus on 3 key pillars, including prevention through HPV vaccination, screening and treatment of pre-cancerous lesions, and management of invasive cervical cancer, including access to palliative care.

To eliminate cervical cancer, the WHO indicated that all countries must reach and maintain an incidence below 4 per 100,000 women-years.

“Ninety percent of girls should be fully vaccinated by 15 years of age, 70% of women should be screened at least twice with a high-performance test by age 45 and 90% of women with precancer or cancer should receive the appropriate care and treatment, including palliative care,” Tedros Adhanom Ghebreyesus, PhD, MSc, BSc, director-general of WHO, explained during a WHO video. “We believe all countries can meet these ambitious goals.”

According to the WHO, achieving these specified targets would yield reductions in both incidence and mortality. Further, by 2030, the median cervical cancer incidence rate would fall by 10%, setting the world on the path to avert 70 million cases in the century.

In an interview with CancerNetwork®, Julie Torode, director of special projects at the Union for International Cancer Control (UICC), discussed the strategy further and how individuals can aid in advocating for the advancement of this global strategy.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.


73rd World Health Assembly Decisions [news release]. Published August 7, 2020. Accessed August 20, 2020. https://www.who.int/news-room/feature-stories/detail/73rd-world-health-assembly-decisions

Related Videos
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
Related Content